索法酮 T4977

Product Introduction
Bioactivity


英文名: Sofalcone

描述: Sofalcone (SU-88) 可诱导血红素加氧酶-1在胃肠上皮中的表达，是一种抗胃溃疡剂。

细胞实验: Primary HUVECs are seeded at 60?000 cells per well and incubated at 37°C for 14 to 16 hours to allow tube formation. Cells are then cultured in the presence of either TNF-α (10 ng/mL) alone, with both TNF-α (10 ng/mL) and Sofalcone 50 μM, or control media for 8 to 12 hours. Tube formation is assessed, and images are captured using microscope at ×4 magnification.

体外活性: Sofalcone (50 μmol/L) significantly increases HO-1 mRNA expression than the control group in both trophoblasts and HUVECs (P<0.05 for both). Western blot analysis shows that Sofalcone potently increases HO-1 protein expression in primary HUVECs treated for 24 hours. Western blot analysis also reveals a significant increase in the amount of Nrf2 in the nuclear fraction of HUVECs with Sofalcone treatment (50 μmol/L) for 6 hours. In primary HUVECs, expression of NQO1, TXN, and GCLC are increased in a dose dependently manner with Sofalcone treatment for 24 hours. Sofalcone significantly decreases the sFlt-1 concentrations in the culture media and dose dependently decreases the amount of THP-1 monocyte adherence to HUVECs.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (110.98 mM)


关键字: inhibit | Sofalcone | Bacterial | SU88 | SU 88 | Inhibitor | Autophagy

相关产品: Nonanoic acid | Closthioamide | 5-Azacytidine | (3R,6R)-Vaborbactam | Licarin B | MAC-545496 | Avibactam sodium | ML406 | Eugenol acetate | Vebufloxacin

相关库: Drug Repurposing Compound Library | Approved Drug Library | ReFRAME Related Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Anti-Cancer Approved Drug Library | Autophagy Compound Library | Nonsteroidal Anti-Inflammatory Compound Library

索法酮 T4977信息由TargetMol中国为您提供，如您想了解更多关于索法酮 T4977报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途